Navigation Links
Signalife Announces Reverse Stock Split, Preferred Stock Dividend and $5 Million Investment
Date:9/10/2008

preferred shares equal to the $5,000,000 divided by the average closing market price for the common shares as of the date of the commitment or investment, whichever is higher (the "target price"). This series of stock will be redeemable (i.e., the investment will be repaid by Signalife) in five years, together with interest accrued at libor plus 2%. The investors may, after a one-year holding period, convert their investment in the series 'B' preferred shares, including accrued interest, into common shares at the ten-day average closing market price for the common shares as of the date of the conversion, but (1) not less the target price, and (2) not more than two-times the target price. Signalife will also have the right, after six months, to convert all of the series 'B' preferred shares, including accrued interest, into common shares at the ten-day average closing market price for the common shares, subject to the same floor and cap prices applicable to conversions by the holders of the series 'B' preferred shares. Each series 'B' preferred share shall be entitled to one vote on all corporate matters that may be submitted to the company's common shareholders, with the common and series 'B' preferred shares voting as a single class. The series 'B' preferred shares will have a liquidation preference over common shares and all other classes of preferred shares, with the exception of outstanding series 'A' preferred shares. The creation and sale of the series 'B' preferred shares may also be subject to applicable regulatory approvals. The company will also register the series 'B' preferred shares (to the extent permitted by the SEC) under a resale registration statement.

Signalife further announced that the board of directors has approved the creation of a new series of convertible preferred stock, to be designated series 'C', and the declaration of a dividend of those shares to all common shareholders and series 'B' preferred shareholders of record as of the
'/>"/>

SOURCE Signalife, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Signalife Announces Anticipated Date of Transition to OTCBB
2. Signalife to Issue Breaking News Regarding Vianale & Vianale Tomorrow
3. Signalife Announces Intent to Withdraw From AMEX and Trade on the OTCBB
4. AFL To Return to Oklahoma Due to Overwhelming Demand for Signalife Heart Screening
5. Signalife Board Approves Merger
6. Signalife Announces AFL Joins NIH Education Program
7. Signalife Appoints Lee Ehrlichman President and Chief Operating Officer
8. Signalife Appoints Lee Ehrlichman as Company Director and Operations Director; Additional Notice Received From Amex Regarding Sharholders Equity Deficiency
9. Signalife Awarded New U.S. Patent, System For, And Method Of, Monitoring Heartbeats Of A Patient
10. Signalife Announces Webcast
11. AMEX Notifies Signalife That It Has Accepted Signalifes Plan of Compliance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... YORK , Sept. 30, 2014 ... and segments with highest potential revenues Do you ... updated report gives you revenue predictions for those ... For those therapies you find financial data, R&D ... analysis you get sales forecasts to 2024 at ...
(Date:9/30/2014)... Proove Biosciences , the commercial and research leader in ... test built upon research from their published P.A.I.N. Study. ... physicians with an objective way to understand theirs patient’s ... individuals. With this new test, physicians will be able ... that will affect their pain tolerance. , The P.A.I.N. ...
(Date:9/30/2014)... 2014 Fast, semi-automatic creation ... in documents ChemAxon , a ... services for life science research, launches ChemCurator, an ... structures from documents. Markush structures are ... generating and understanding Markush structures is a difficult ...
(Date:9/30/2014)... 30, 2014 BioHealth Innovation, Inc. ... biohealth innovations and increasing access to early-stage funding in ... venture capitalist, Tania Fernandez , Ph.D., has joined ... will be a member of the management team for ... to $50 million in seed and early-stage equity investments ...
Breaking Biology Technology:Biosimilars and Follow-On Biologics: World Industry and Market Prospects 2014-2024 2Biosimilars and Follow-On Biologics: World Industry and Market Prospects 2014-2024 3Biosimilars and Follow-On Biologics: World Industry and Market Prospects 2014-2024 4Biosimilars and Follow-On Biologics: World Industry and Market Prospects 2014-2024 5Proove Biosciences is Now Offering the Proove Pain Perception Genetic Test to Help Physicians Assess Patient Pain Tolerance Levels 2Proove Biosciences is Now Offering the Proove Pain Perception Genetic Test to Help Physicians Assess Patient Pain Tolerance Levels 3ChemAxon Introduces ChemCurator for Chemical Information Extraction and Markush Structure Creation 2Seasoned Life Sciences Venture Capitalist Tania Fernandez Joins BHI to Help Manage New BioHealth Gap Fund 2
... convertible notes, and extended the maturity to 2011 on an additional $23.25 ... ... Cell Therapeutics, Inc.,("CTI" or the "Company") (Nasdaq and MTAX: CTIC) today announced ... "New Notes") due 2011 and 5,459,574 shares of its common stock,no par ...
... Biosciences,Inc. (Nasdaq: NBIX ) announced today that the ... Administration (FDA) indicating,that the New Drug Application (NDA) for ... of insomnia is approvable pending additional clinical and,preclinical data., ... action letter from the FDA,stating that indiplon 5 mg ...
... Company Mails Letter to Shareholders, MONTVALE, N.J., ... today announced that Glass Lewis & Co., one ... that Datascope,shareholders re-elect the Board,s nominees -- James ... Company,s Annual Meeting of Shareholders on,Thursday, December 20, ...
Cached Biology Technology:Cell Therapeutics, Inc. Announces Issuance of $23.25 Million in New Convertible Senior Notes in Exchange for $36.08 Million of Existing Convertible Senior Subordinated and Subordinated Notes 2Cell Therapeutics, Inc. Announces Issuance of $23.25 Million in New Convertible Senior Notes in Exchange for $36.08 Million of Existing Convertible Senior Subordinated and Subordinated Notes 3Neurocrine Receives Approvable Letter for Indiplon Capsules with Additional Safety and Efficacy Data Required by FDA 2Neurocrine Receives Approvable Letter for Indiplon Capsules with Additional Safety and Efficacy Data Required by FDA 3Glass Lewis Recommends Datascope Shareholders Vote for Re-Election of the Board's Directors 2Glass Lewis Recommends Datascope Shareholders Vote for Re-Election of the Board's Directors 3Glass Lewis Recommends Datascope Shareholders Vote for Re-Election of the Board's Directors 4Glass Lewis Recommends Datascope Shareholders Vote for Re-Election of the Board's Directors 5Glass Lewis Recommends Datascope Shareholders Vote for Re-Election of the Board's Directors 6Glass Lewis Recommends Datascope Shareholders Vote for Re-Election of the Board's Directors 7
(Date:9/30/2014)... engineers, led by Clemson University associate professor Brian ... from the U.S. Department of Energy,s Experimental Program ... positive impact on South Carolina in the advancement ... , "Understanding the scientific and engineering needs for ... nuclear technologies is imperative if South Carolina is ...
(Date:9/30/2014)... DURHAM, N.C. -- Pollution in urban and farm runoff ... a new study finds. , The study, published ... shows that nitrogen in the runoff ends up in ... tumors on the animals, eyes, flippers and internal organs. ... and the National Oceanic and Atmospheric Administration (NOAA) conducted ...
(Date:9/30/2014)... release is available in German . ... their behavioural response to risky situations such as exposure ... Ornithology now found in a long-term study on different ... both metabolic rate and ambient temperature. High metabolic rates ... as in these scenarios birds were more likely to ...
Breaking Biology News(10 mins):Researchers get $5.25 million to advance nuclear technologies in South Carolina 2Pollution linked to lethal sea turtle tumors 2Pollution linked to lethal sea turtle tumors 3Risky metabolism 2
... Research on Aging (Novato, CA) and Biotica Technology Ltd. ... polyketides in diseases of aging. Building on observations that ... Kennedy; Nature 2009), the collaborators will evaluate ... of age-related disease models to identify novel therapeutics. ...
... no crime. Consider that some strains of algae ... the less harmful varieties suck oxygen out of water, ... Recent algal blooms in the Great Lakes, for instance, ... Andr Hudson and colleagues have figured out how to ...
... Cornell University researchers may have solved a 100-year puzzle: ... that therapies to treat Alzheimer,s disease, multiple sclerosis and cancers ... Journal of Neuroscience , Sept. 14, 2011.) , The ... can modulate the entry of large molecules into the brain. ...
Cached Biology News:Buck Institute and Biotica to investigate polyketides in extension of healthy lifespan 2Outsmarting algae -- RIT scientist finds the turn-off switch 2Breaching the blood-brain barrier 2
...
... XT is undoubtedly the most complete and ... concept of layers and subsets makes it ... for different data outputs, for example Cy3 ... as well as different subsets of genes ...
...
...
Biology Products: